Siltuximab

Information

Assessment report

Assessment report for Sylvant (siltuximab), 20 March 2014, EMA/CHMP/258608/2014.

"No environmental risk assessment was submitted. In accordance with the Guideline on the environmental risk assessment (ERA) of medicinal products for human use [EMEA/CHMP/SWP/4447/00], peptides and proteins are excluded from the need for an environmental risk assessment. Therefore, an ERA for siltuximab is not required."

Fass environmental information

Fass environmental information for Sylvant from Janssen (downloaded 2019-09-04).

Risk

The use of amino acids, proteins and peptides is not expected to have any environmental impact.

Detailed information

According to the European Medicines Agency guideline on environmental risk assessments for pharmaceuticals (EMA/CHMP/SWP/4447/00), vitamins, electrolytes, amino acids, peptides, proteins, carbohydrates, lipids proteins, vaccines and herbal medicinal products are exempted because they are unlikely to result in significant risk to the environment.